Nationwide trends in radiotherapy use among older patients with early-stage non-small cell lung cancer in Japan, 2013–2022

Le résumé fourni par la source

This study examined trends in radiotherapy use among older patients with early-stage non-small cell lung cancer (NSCLC) in Japan. Using hospital-based cancer registry data (2013–2022), we analyzed 295,662 patients aged ≥ 65 years with epithelial lung tumors (clinical Tis–T2N0M0), excluding those with poorly differentiated endocrine carcinoma or missing treatment data. Overall, 80% underwent surgery, 11% received radiotherapy, and 9% received other management. Radiotherapy use increased from 10.5% in 2013 to 12.8% in 2022 (age- and sex-standardized increase of + 1.2% points). Logistic regression showed increased odds of radiotherapy use in the later period across subgroups according to age, sex, clinical T category, and facility volume, except among patients aged 75–84 years and those treated at high-volume facilities. From 2013 to 2022, radiotherapy use changed by + 1.7, + 0.2, and + 4.5% points among patients aged 65–74, 75–84, and ≥ 85 years, reaching 6.2%, 14.8%, and 35.5%, respectively. Surgery use changed by − 2.1, + 1.3, and − 3.2% points, with values of 89.6%, 76.3%, and 32.8%, respectively. Radiotherapy use increased only modestly, with variation across age groups. Over 30% of patients aged ≥ 85 years underwent surgery, indicating the need to clarify the roles of surgery and radiotherapy in this population.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.